Close Menu

NEW YORK – German cellular analytics firm Evorion Biotechnologies said on Tuesday that it has formed a strategic partnership with Jüke Systemtechnik and closed a financing round for an undisclosed amount to support commercialization of Evorion's cellular analysis platform.

Münster-based Evorion said that new and existing investors, including Jüke, participated in the financing round, with Jüke becoming an Evorion shareholder.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.